Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Adrestia Therapeutics","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$1,150.0 million","upfrontCash":"Undisclosed","newsHeadline":"GSK and Ahren Announce Co-Led Series A Investment in Adrestia, and Multi-Project Discovery Collaboration for Five Projects","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Discovery Platform","country":"UNITED KINGDOM","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Adrestia Therapeutics","sponsor":"Proteros","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Proteros and Adrestia Initiate Multi-Target Partnership to Discover First-In-Class Drugs for Intractable Genetic Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Undisclosed","date":"October 2022","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery"}]

    Find Clinical Drug Pipeline Developments & Deals by Adrestia Therapeutics

    Menu

    Adrestia Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Adrestia Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Proteros and Adrestia Initiate Multi-Target Partnership to Discover First-In-Class Drugs for Intractable Genetic Diseases

              Details:

              The partnership brings together Proteros’ discovery capabilities which are tailored to unlock even the most technically challenging drug targets with Adrestia’s expertise in target biology with a novel synthetic rescue drug development platform.

              Lead Product(s): Undisclosed

              Therapeutic Area: Genetic Disease Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Small molecule

              Recipient: Proteros

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership October 25, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Adrestia Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              GSK and Ahren Announce Co-Led Series A Investment in Adrestia, and Multi-Project Discovery Collaboration for Five Projects

              Details:

              The collaboration will combine Adrestia’s world leading, synthetic viability platform with GSK’s deep scientific expertise in human genetics, functional genomics, screening, and bioinformatics.

              Lead Product(s): Undisclosed

              Therapeutic Area: Rare Diseases and Disorders Product Name: Undisclosed

              Highest Development Status: Discovery Platform Product Type: Undisclosed

              Partner/Sponsor/Collaborator: GSK

              Deal Size: $1,150.0 million Upfront Cash: Undisclosed

              Deal Type: Collaboration December 18, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY